Skip to main
DWTX
DWTX logo

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. is advancing its drug development pipeline with promising product candidates aimed at treating conditions associated with virus-triggered immune responses, highlighting its focus on addressing significant unmet medical needs. The recent licensing agreement with Serpin Pharma for the global rights to SP16 indicates strategic growth and diversification efforts, further enhancing the company's position in the biopharmaceutical market. Additionally, the upward revision of the 12-month price target reflects the potential future revenues from these assets, signaling increased confidence in the company's financial performance and market trajectory.

Bears say

Dogwood Therapeutics Inc, a development-stage biotechnology company, has a challenging outlook primarily due to its reliance on the success of its novel antiviral therapies, IMC-1 and IMC-2, which are still in the early stages of development. The company faces considerable risks associated with the clinical trial process, including potential delays and the uncertainty of regulatory approval, which may hinder its ability to generate revenue in the near term. Additionally, an analysis of Dogwood's financials indicates a lack of significant funding commitments, creating concerns over its sustainability and ability to finance ongoing research and development efforts.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.